WASHINGTON – President Donald Trump on Saturday signed an executive order aimed at accelerating federal review of psychedelic drugs for medical use, marking a significant shift in how Washington approaches treatment for serious mental illness. The order, titled “Accelerating Medical Treatments for Serious Mental Illnesses,” is designed to speed research and potential access to psychedelic-based therapies for Americans suffering from severe psychiatric conditions.
Trump said the order is meant to confront what the administration described as the growing burden of suicide and serious mental illness in the United States. He told reporters during the signing that the measure would help ensure people suffering from debilitating symptoms may finally get a chance to reclaim their lives. The executive order specifically opens the door to expedited review of psychedelics, including ibogaine, which remains classified as a Schedule I drug under federal law.
The move did not come out of nowhere. What prompted Trump to sign the order was mounting pressure from veterans, advocates, and public figures who have argued for years that traditional mental health treatments are failing too many Americans, especially those suffering from PTSD, trauma, addiction, and treatment-resistant depression. Reuters reported that ibogaine and other psychedelic therapies have drawn increasing attention from veterans seeking alternatives after conventional treatment options came up short.
That issue has been especially pronounced among combat veterans, some of whom have traveled outside the United States, particularly to clinics in Mexico, to pursue ibogaine-based treatment because it remains illegal here. The growing visibility of those cases helped push the issue into the national spotlight and created additional pressure on the federal government to reconsider long-standing roadblocks to research and medical access.
The White House said the order is intended to remove barriers that have slowed the development of new treatments for severe mental illness and to make promising therapies more accessible in carefully defined cases. The administration tied the order directly to rising suicide rates and the broader mental health crisis, including the worsening strain seen during the COVID-19 era and under the Biden administration.
Trump was joined at the signing ceremony by Health and Human Services Secretary Robert F. Kennedy Jr., podcaster Joe Rogan, and former Navy SEAL Marcus Luttrell. Their presence underscored how the issue has moved from the political margins into the mainstream, powered in part by veteran advocacy and a growing public conversation around psychedelic-assisted treatment.
Rogan has long discussed psychedelic therapies on his podcast, while Kennedy has expressed support for expanded research into substances such as ibogaine. At the state level, interest has also been growing, with Texas among the states investing in ibogaine-related research, particularly with veterans in mind.
Even so, the issue remains controversial. Ibogaine is still federally restricted, and major news outlets covering the order noted that safety concerns remain, including potential heart-related risks and broader questions about how quickly these substances should move from research settings into approved treatment pathways.
Still, Trump’s order represents a notable break from the old federal posture. For years, psychedelic therapies were largely dismissed or politically untouchable. Now, with veterans, mental health advocates, and high-profile public figures pushing the issue harder, the Trump administration is betting that accelerated review may offer hope to Americans who believe the current system has left them behind.
Janet Mills and her brother are already acting, with their CCP associates, to acquire more Maine homes to convert to LSD labs !!